• HRP Proximity Labeling of Cell-Surface Proteins

  2026-10-08

  Wu and colleagues describe a cell-type-specific HRP proximity-labeling framework for profiling cell-surface proteins in mouse brain tissue. By combining genetically targeted HRP, localized biotin deposition, streptavidin enrichment, mass spectrometry, and multiple validation layers, the study extends cell-surface proteomics into complex tissue while emphasizing that detected proteins remain putative until independently validated.

• Topotecan vs Paclitaxel in Ovarian Cancer

  2026-10-08

  The 1999 review by Kollmannsberger and colleagues presents topotecan as a water-soluble topoisomerase I inhibitor whose pharmacology, toxicity, and early clinical activity distinguished it from microtubule-directed agents such as Paclitaxel. Its most clinically meaningful evidence was activity in ovarian cancer, including a randomized comparison in previously treated patients, although the review’s conclusions are limited by its era and by the absence of modern comparative treatment contexts.

• Etoposide (VP-16): Five Evidence Questions

  2026-10-07

  A source-grounded overview of how Etoposide is understood as a DNA-damaging research compound, what the HITT–ATM study shows, and where evidence from cell, animal, tissue, and supplier sources cannot be extended.

• MK-2206 Dihydrochloride: Evidence and Context

  2026-10-07

  MK-2206 dihydrochloride is described as a selective allosteric Akt1/2/3 inhibitor, but the supplied peer-reviewed study evaluates ginkgolide C rather than MK-2206. This overview separates catalog claims from published findings, explains how Akt pathway inhibition could serve as a conceptual mechanistic test, and outlines limits when translating evidence between cancer, neuronal, and microglial models.

• Etoposide (VP-16) and DNA Damage Research Context

  2026-10-06

  Etoposide (VP-16) is a widely used topoisomerase II–targeting reference compound in cancer biology, while triptolide has been reported to impair DNA-PKcs-dependent repair. This overview compares their research contexts, explains what DNA damage and repair readouts can—and cannot—show, and distinguishes peer-reviewed findings from supplier-reported product information.

• Radioiodinated Balsalazide for Colitis Imaging

  2026-10-06

  Sanad and colleagues investigated radioiodinated balsalazide as a candidate tracer for detecting ulcerative colitis in mice, combining radiochemical characterization with comparative biodistribution. The reported accumulation in ulcerated colon supports further preclinical evaluation, while the study’s animal model, short observation window, and indirect evidence for receptor selectivity limit clinical interpretation.

• From WecA Kinetics to Translational Strategy

  2026-10-05

  A translational perspective on WecA as a membrane-enzyme target in tuberculosis drug discovery, interpreting the 2026 kinetic study while separating biochemical evidence from whole-cell and clinical validation. The article also positions Miransertib as a separate catalog resource rather than implying unsupported activity against WecA.

• CHIR-99021 (CT99021) HCl Product Overview

  2026-10-05

  CHIR-99021 (CT99021) HCl is an APExBIO-listed small-molecule GSK-3α/β inhibitor for conceptual research in cell signaling and stem-cell biology. No directly matched paper evidence was provided, so supplier claims should not be treated as independently validated findings.

• Norepinephrine-to-Angiotensin II Conversion Ratio

  2026-10-04

  A post-hoc analysis of the ARAMIS trial estimated a norepinephrine-to-angiotensin II conversion dose ratio of 10:1 when norepinephrine was expressed as bitartrate, or 5:1 as norepinephrine base. The study provides a clinically relevant framework for comparing vasopressor exposure, while its small, single-center observational design limits use of the ratio as a universal dosing rule.

• Promethazine HCl and Host-Directed Immunity

  2026-10-03

  A source-grounded perspective on how Promethazine HCl fits into host-directed antibacterial research, with emphasis on macrophage biology, evidence boundaries, translational study design, and product provenance.

• ATG4B Nuclear Translocation and AML DNA Repair

  2026-10-01

  This study identifies an energy-sensitive ATG4B–PRMT1–MRE11 axis that connects metabolic stress with defective DNA repair and leukemia progression. Its combination of mechanistic cell studies, genetically defined AML models, and patient-derived xenografts provides a useful framework for evaluating how metabolic state influences genomic stability, while requiring careful validation before transfer to other disease or drug-discovery settings.

• Rotigotine hydrochloride Assay Guide

  2026-10-01

  A scenario-based guide to using Rotigotine hydrochloride (SKU A3777) in cell viability, neuroprotection, proliferation, and cytotoxicity workflows. It connects concentration selection, solvent control, route-dependent interpretation, and vendor evaluation with product data and peer-reviewed Parkinson’s disease research.

• Sodium Citrate for Reproducible 3D SERS Arrays

  2026-10-01

  Sodium citrate provides a practical chemistry variable for tuning gold nanoparticle assembly on polymer-pen-lithography patterns. This workflow connects citrate-controlled dispersion and metal-ion coordination with reproducible 3D SERS substrate fabrication, while separating literature-demonstrated performance from recommended optimization experiments.

• Diuron C6731 for Reliable Cell Toxicology Assays

  2026-09-30

  This scenario-driven guide shows how Diuron (SKU C6731) can support more interpretable cell viability, proliferation, and cytotoxicity experiments. It connects formulation, assay compatibility, dose-response design, and recent evidence on JAK2/STAT1 signaling in Diuron-associated renal injury.

• Doxycycline Hyclate in MMP-2/9 BBB Research

  2026-09-29

  Doxycycline hyclate is a matrix metalloproteinases inhibitor that can function as a mechanistic probe in blood–brain barrier research. This article explains how to distinguish MMP-dependent protection from broader anti-inflammatory or antimicrobial effects when designing translational assays.

8289 records 1/553 page Next 12345 下5页 Last page